GlobeNewswire

Nyxoah and Vanderbilt University enter exclusive licensing agreement regarding next generation neurostimulation technologies to treat Obstructive Sleep Apnea (OSA)

Share

A picture containing clock, light, drawing  Description automatically generated

PRESS RELEASE

Nyxoah and Vanderbilt University enter exclusive licensing agreement regarding next generation neurostimulation technologies to treat Obstructive Sleep Apnea (OSA)

Mont-Saint-Guibert, Belgium – 2nd February, 2021 – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has signed an exclusive license agreement with Vandebilt University, Nashville – TN, USA.
The agreement allows Nyxoah to further develop new neurostimulation technologies for the treatment of sleep disordered breathing conditions that were invented by Dr. David T. Kent. New treatments will focus, among others, on stimulating the ansa cervicalis, the efferent fiber of the glossopharyngeal nerve or nerves that innervate the palatoglossus and/or the palatopharyngeus muscle. Nyxoah will also work together with Vanderbilt University to continue prosecution of patent applications, which will give Nyxoah the exclusive right to use these new technologies once patents will be granted.
Nyxoah agreed to pay Vanderbilt an up-front fee as well as payments based on regulatory, development and commercialization milestones. Nyxoah also agreed to pay royalties on future product sales.
Under this agreement, Nyxoah shall develop a next generation neurostimulation-based solution to treat Obstructive Sleep Apnea patients. Obstructive Sleep Apnea is the most common sleep disordered breathing condition, affecting almost 1 billion people globally1. Over the past decade, neurostimulation therapies, such as the proprietary Genio® system developed and commercialized by Nyxoah, have proven their long-term efficacy in efficiently treating OSA patients.

Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “We are delighted to start collaborating  with Vanderbilt University, a worldwide recognized US university in this field of research, through this exclusive licensing agreement. This will open new horizons in the field of neurostimulation technologies, improving and expanding current treatment solutions for OSA patients, and will reinforce Nyxoah’s future pipeline. The upcoming collaboration with Dr. Kent at Vanderbilt University Medical Center, together with Nyxoah’s groundbreaking approach in neurostimulation and its collaboration with international key opinions leaders, will help Nyxoah strengthen its position as innovator offering patient-centered solutions.”

Dr. David T. Kent from Vanderbilt University added: “Partnering with Nyxoah  creates the opportunity to build new technologies based on Vanderbilt’s intellectual property. We share the same vision of developing disruptive solutions, always having in mind that patients should be put at the center. Our mission will be to demonstrate the unique potential of such new technologies resulting in a broader OSA treatment portfolio.”

- ENDS -

For further information, please contact:

Nyxoah
Milena Venkova, Corporate Communications Manager
milena.venkova@nyxoah.com
+32 490 11 93 57

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk2 and comorbidities including cardiovascular diseases, depression and stroke.
Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.
For more information, please visit www.nyxoah.com.

About Vanderbilt University
Vanderbilt University, located in Nashville – Tennessee, USA, is a private research university offering a full range of undergraduate, graduate and professional degrees.
For more information, please visit www.vanderbilt.edu.

Caution – Genio® is CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.





1 Benjafield, Adam V et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med 2019 Published Online July 9, 2019 http://dx.doi.org/10.1016/S2213-2600(19)30198-5



2 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071–1078.



Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Eurocastle Releases Fourth Quarter and Year End 2020 Financial Results5.3.2021 08:00:00 CETPress release

Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Mark Woodall Tel: +44 1481 723450 Eurocastle Releases Fourth Quarter and Year End 2020 Financial Results ­­ Guernsey, 5 March 2021 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) today has released its annual report for the year ended 31 December 2020. Adjusted Net Asset Value (“NAV”) of €16.7 million1, or €9.00 per share2 up €1.54 per share vs. €7.46 per share at Q3 2020 (up €0.68 per share vs. €8.32 per share at YE 2019) due to: Valuation movements: €0.20 per share, or 4%, increase in Q4 2020 (€1.03 per share3 decrease for the FY 2020) on the remaining three real estate fund investments.€0.02 per share, or 4%, increase in Q4 2020 (€0.05 per share increase for the FY 2020) on the remaining three NPL and other loan interests. Positive reserve and legacy movements of €1.32 per share in Q4 2020 (€1.66 per share increase for the FY 2020) IFRS NAV of €32.9 million, or €17.72 per share 2020 Capital Distribut

AB Klaipėdos nafta preliminary revenue for February 20215.3.2021 08:00:00 CETPress release

The preliminary sales revenue of the Company’s oil terminals for February 2021 comprises EUR 1.3 million and is lower by EUR 0.8 million or by 38.1 % compared to February of 2020. The preliminary sales revenue of the Company’s oil terminals for the two months of 2021 comprises EUR 3.6 million and is lower by 12.2 % compared to the same period of 2020. The preliminary sales revenue of the Company’s Klaipėda LNG terminal for February 2021 comprises EUR 2.7 million (during the same month of 2020 – EUR 3.6 million). Klaipėda LNG terminal revenue from regulated activities consists of the regasification tariff fixed part (for booked annual capacities), variable part for amount of re-gasified LNG and reloading revenue. The level of Klaipėda LNG terminal revenue (for booked annual capacities) does not depend on regasification volume. Revenue is confirmed by the National Energy Regulatory Council (NERC) based on the approved methodology of State regulated prices in the natural gas sector and is

Nexstim Abp har publicerat sin årsrapport för 20205.3.2021 08:00:00 CETPressemelding

Företagsmeddelande, Helsingfors, 5 mars 2021 kl. 9.00 (EET) Nexstim Abp har publicerat sin årsrapport för 2020 Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) meddelar att bolaget har publicerat sin årsrapport för 2020. Dokumenten som ingår i rapporten är tillgängliga under "Investor Relations" på bolagets webbplats på nexstim.com/investors/financial-reports-and-presentations. I årsrapporten ingår verksamhetsberättelse, moderbolagets och koncernens bokslut samt revisionsberättelse. Kopia av årsrapporten bifogas detta meddelande. NEXSTIM ABP Mikko Karvinen, verkställande direktör För mer information gå in på bolagets webbplats på www.nexstim.com eller kontakta: Mikko Karvinen, verkställande direktör +358 50 326 4101 mikko.karvinen@nexstim.com Erik Penser Bank AB (Certified Adviser) +46 8 463 83 00 certifiedadviser@penser.se Om Nexstim Abp Nexstim är ett finländskt medicinteknikbolag som verkar på den globala marknaden. Vår mission är att möjliggöra individualiserad och ef

Cavotec to focus on growing markets for sustainability solutions in Ports & Maritime and Industry – Initiates process to divest the Airports business5.3.2021 08:00:00 CETPress release

Cavotec will focus resources and make investments to further develop its leading position within electrification and automation for improved sustainability in its fast-growing ports & maritime and specialized industrial applications markets and, as a consequence, will divest its Airports business. As the market trends and regulatory requirements are expected to drive significant growth in demand for shore power, automated mooring and port and industry electrification, Cavotec has decided to focus resources and investments in these areas to further strengthen its position and accelerate its growth. Cavotec has subsequently taken a decision to initiate a process to divest its Airports business. Currently, Airports accounts for approximately 25 per cent of Cavotec’s revenue with about 240 employees. Cavotec estimates that a sale of the Airports business can be completed during 2021. In future Cavotec will report Airports separately, commencing with the interim report for the first quarter

Nexstim Plc Publishes 2020 Annual Report5.3.2021 08:00:00 CETPress release

Company announcement, Helsinki, 5 March 2021 at 09.00 am (EET) Nexstim Plc Publishes 2020 Annual Report Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the publication of its 2020 Annual Report. These documents are available on the "Investor Relations" section of the Company's website at nexstim.com/investors/financial-reports-and-presentations. The Annual Report includes the Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor's Report. A copy of the Annual Report is attached to this announcement. NEXSTIM PLC Mikko Karvinen, CEO Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO +358 50 326 4101 mikko.karvinen@nexstim.com Erik Penser Bank AB (Certified Adviser) +46 8 463 83 00 certifiedadviser@penser.se About Nexstim Plc Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and

Norsk Hydro: Invitation to Investor presentation - Hydro agrees to sell Rolling business area to KPS Capital Partners5.3.2021 07:31:00 CETPress release

President & CEO, Hilde Merete Aasheim, will present the transaction by an audio webcast and a conference call, in English, at 09:00 CET today, Friday 5 March. In order to listen to the presentation, please join the audio webcast. There will be a Q&A session directly after the presentation. If you would like to ask questions, you need to join the conference call before end of the presentation. Please see details below. It will not be possible to ask questions on the audio webcast. To join the conference call, please use the below “Click to Join” link 5-10 minutes prior to start time. You will be asked to enter your phone number and registration details. The Event Conferencing system will call you on the phone number you provide and place you into the event. Please note that the “Click to Join” link becomes active 15 minutes prior to the scheduled start time. Please use the “Click to Join” option for the easiest way to join the conference call. Click to Join Call 09:00 CET >> As an alter

Norsk Hydro: Invitasjon til Investorpresentasjon - Hydro selger forretningsområdet Rolling til KPS Capital Partners5.3.2021 07:31:00 CETPressemelding

Konsernsjef Hilde Merete Aasheim vil presentere transaksjonen i dag, fredag 5. mars kl. 09.00 (norsk tid) via audio webcast og telefonkonferanse. Presentasjonen kan følges via audio webcast. Det vil være mulig å stille spørsmål rett etter presentasjonen. For å stille spørsmål må du være koblet på telefonkonferansen før presentasjonen er ferdig. Se detaljer nedenfor. Det vil ikke være mulig å stille spørsmål via audio webcast. Du melder deg på telefonkonferansen ved å klikke på lenken “Click to Join“ 5-10 minutter før start. Du må oppgi telefonnummer og registreringsdetaljer. Konferansesystemet vil ringe tilbake på det oppgitte telefonnummeret og koble deg til konferansen. “Click to Join“-lenken vil være aktiv fra 15 minutter før planlagt start. Vennligst bruk “Click to Join“ for den enkleste måten å delta på telefonkonferansen. Click to Join Call 09:00 CET >> Alternativt kan du ringe numrene nedenfor for telefonkonferansen: Norge +47 2100 2613 UK +44 (0)330 336 9104 USA +1 323-794-2442